Kimball Electronics (KE) Q3 2026 earnings review
Headline Revenue Decline Masks Underlying Stabilization
Kimball Electronics reported a 6% YoY decline in Q3 revenue to $352.9M, but this headline is a mirage. Adjusting for a non-recurring $24M consigned medical inventory sale in the year-ago quarter, core revenue was actually slightly positive (+0.6% YoY). The strategic pivot to a Medical Contract Manufacturing Organization (CMO) is accelerating, with Medical segment sales growing 10% sequentially. Profitability remains stable: Adjusted Operating Margin held steady at 4.2%. Management confidently affirmed full-year guidance and signaled they expect margins to land at the high end of their targeted range, showing strong execution despite lingering weakness in Automotive and Industrial end markets.
🐂 Bull Case
Medical sales hit $106.1M, achieving double-digit (10%) sequential growth from Q2's $96.3M. Excluding the $24M one-time comp from Q3 2025, underlying organic Medical growth was an impressive ~16% YoY.
Despite lower reported sales, Gross Profit expanded to $27.8M (7.9% margin) from $26.9M (7.2% margin) a year ago. The company successfully absorbed the loss of fixed-cost leverage and prior divested segments.
🐻 Bear Case
Automotive sales contracted 3% YoY to $160.5M, and Industrial fell 8% YoY to $86.3M. The continued softness in traditional EMS markets is capping total company top-line potential.
Nine-month Operating Cash Flow plummeted to $29.8M from $105.9M in the prior year. While still positive, the massive working capital tailwinds (inventory liquidation) seen in FY25 have evaporated.
⚖️ Verdict: 🟢
Bullish. The 6% revenue decline is an optical illusion created by a prior-year one-off event. The underlying fundamentals show an accelerating, higher-margin Medical CMO business effectively bridging the gap left by cyclical industrial and auto weakness. Margins are holding firm.
Key Themes
Medical CMO Pivot is Accelerating
The long-telegraphed shift to Medical CMO is bearing fruit. Q3 Medical sales of $106.1M represented 30% of total revenue. More importantly, this represents a 10% sequential increase from Q2's $96.3M. The company explicitly noted that once new capacities (like the new Indianapolis facility) ramp up, this will become a 'meaningful driver of both top line growth and margin expansion.'
M&A Pipeline Activated
CEO Richard Phillips explicitly highlighted inorganic growth as a 'possible complement' to the Medical CMO strategy. Coming off previous quarters where management described themselves as 'balance sheet first' and cautious on M&A, this explicit mention suggests Kimball is actively hunting for tuck-in acquisitions to accelerate scale and capabilities in the medical space.
Automotive Continues to Decelerate
Automotive sales of $160.5M fell 3% YoY. While an improvement from Q2's 13% YoY drop, it remains a consistent drag. Management has previously cited the loss of an electronic braking program and broad macro softness; Q3 results confirm that the Auto segment has not yet found its structural bottom.
SG&A Creep Compresses Operating Leverage
Selling and Administrative expenses rose to $15.2M (4.4% of sales) from $13.2M (3.6% of sales) a year ago. Even on an adjusted basis, S&A rose from $11.2M to $13.0M. Management previously warned this would happen as they invest in technology and business development for the Medical CMO ramp, but it requires careful monitoring to ensure these investments yield proportionate revenue.
Other KPIs
Decelerating sharply from $105.9M in the prior year. This drop primarily reflects the normalization of working capital; FY25 saw an aggressive $100M+ inventory destocking effort that artificially inflated cash flows. The company has now strung together nine consecutive quarters of positive OCF, but at a structurally lower, normalized run rate.
Accelerating from 7.2% a year ago. Despite a $21.7M drop in total sales, absolute Gross Profit increased by $0.9M. This signals improved product mix (higher concentration of Medical) and structural cost savings following the closure of the Tampa facility earlier in the fiscal year.
Guidance
Stable. Guidance was affirmed. Subtracting the nine-month actuals ($1,059.8M) implies a Q4 revenue midpoint of $370.2M. This would represent a ~2.7% YoY decline from 25Q4's $380.5M, suggesting management anticipates sequential growth from Q3 but continued slight YoY weakness in legacy segments.
Accelerating. The company affirmed guidance but specifically noted results are 'expected at the high end of the range'. Given the nine-month actual sits at 4.5%, management is essentially guiding for Q4 margins to remain structurally robust despite ongoing S&A investments.
Stable. Affirmed. Nine-month investing outflows sit at $38.1M, meaning $12M to $22M will be deployed in Q4. A significant portion of this continues to fund the build-out of the new 300,000 sq ft medical manufacturing facility in Indianapolis.
Key Questions
M&A Targets and Multiples
You explicitly mentioned inorganic growth as a complement to the Medical strategy. Are you seeing rationalization in medical CMO valuation multiples, and what specific capability gaps (e.g., cold chain, sterilization) are you targeting?
Automotive Stabilization Timeline
Automotive sales continue to contract. Have we fully lapped the impact of the lost Reynosa braking program, and what is your baseline expectation for Auto volume in FY27?
SG&A Run-Rate
Adjusted S&A has risen by roughly $2M year-over-year in the quarter. As the Indianapolis medical facility completes its ramp-up, should we expect S&A as a percentage of sales to plateau, or will it remain elevated near 4%?